Sun Pharma FY27 Q1: India Leadership and Innovation Compounding Keep the Sun Shining!

Research evidence excerpt

Sun Pharma FY27 Q1: India Leadership and Innovation Compounding Keep the Sun Shining!

omous LLP, Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 and Sanford C. Bernstein (India)

Private Limited. For information relating to “Autonomous” branded products (including certain Sales materials) please visit:

www.autonomous.com. For information relating to Bernstein branded products please visit: www.bernsteinresearch.com.

Analysts are compensated based on aggregate contributions to the research franchise as measured by account penetration,

productivity and proactivity of investment ideas. No analysts are compensated based on performance in, or contributions to,

generating investment banking revenues.

This report has been produced by an independent analyst as defined in Article 3 (1)(34)(i) of EU 596/2014 Market Abuse

Regulation (“MAR”) and the same article of MAR as it forms part of United Kingdom domestic law by virtue of the European Union

(Withdrawal) Act 2018.

To our readers in the United States: Bernstein Institutional Services LLC, a broker-dealer registered with the U.S. Securities

and Exchange Commission (“SEC”) and a member of the U.S. Financial Industry Regulatory Authority, Inc. (“FINRA”) is distributing

this publication in the United States and accepts responsibility for its contents. Where this material contains an analysis of debt

product(s), such material is intended only for institutional investors and is not subject to the US independence and disclosure

standards applicable to debt research prepared for retail investors.

Bernstein Institutional Services LLC may act as principal for its own account or as agent for another person (including an affiliate)

in sales or purchases of any security which is a subject of this report.